D228

• Description :

  D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM) . D228 is effective against inflammatory bowel disease (IBD) . D228 alleviates the DSS (HY-116282C) -induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling[1].

• UNSPSC :

  12352005

• Target :

  MyD88; p38 MAPK

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/d228.html

• Purity :

  99.77

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CC1=C(C(/C(O1)=C(C)\C)=O)O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O2

• Molecular Formula :

  C22H28O12

• Molecular Weight :

  484.45

• References & Citations :

  [1]Tang ML, et al. From Hit to Lead: Discovery of First-In-Class Furanone Glycoside D228 Derived from Chimonanthus salicifolius for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2024 Oct 10;67 (19) :17101-17123.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2676188-98-8]